On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Jane Perlmutter

ResearcherPublications, citations & collaboration network

Jane Perlmutter is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Jane Perlmutter have?

ScholarIQindexed works

Jane Perlmutter has 212 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Jane Perlmutter have?

ScholarIQcitation count

Jane Perlmutter has 17,801 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Jane Perlmutter?

ScholarIQh-index

Jane Perlmutter has an h-index of 43 in OpenAlex.

What is the i10-index of Jane Perlmutter?

ScholarIQi10-index

Jane Perlmutter has an i10-index of 88 in OpenAlex.

What is the ORCID of Jane Perlmutter?

ScholarIQorcid

The ORCID for Jane Perlmutter is on the source record.

What is the OpenAlex record for Jane Perlmutter?

ScholarIQopenalex

The OpenAlex for Jane Perlmutter is on the source record.

What are the most-cited papers on Jane Perlmutter?

ScholarIQmost cited works
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Kimberly H. Allison, M. Elizabeth H. Hammond, Mitch Dowsett, Shannon McKernin, Lisa A. Carey, Patrick L. Fitzgibbons, Daniel F. Hayes, Sunil R. Lakhani, Mariana Chávez‐MacGregor, Jane Perlmutter, Charles M. Perou, Meredith M. Regan, David L. Rimm, W. Fraser Symmans, Emina Torlakovic, Leticia Varella, Giuseppe Viale, Tracey Weisberg, Lisa M. McShane, Antonio C. Wolff
Journal of Clinical Oncology. 20201,541 CitationsOPEN ACCESS
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Nora Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-Reasor, Catherine Parker, Marie Catherine Lee, Tufia C. Haddad, Ronald Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman
JAMA Oncology. 2020715 CitationsOPEN ACCESS
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Meredith Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Jane Yuet Ching Hui, Kathleen Kemmer, Anthony Elias, Kirsten K. Edmiston, David Euhus, Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman
New England Journal of Medicine. 2016561 CitationsOPEN ACCESS
Adaptive Randomization of Neratinib in Early Breast Cancer
John W. Park, Minetta C. Liu, Douglas Yee, Christina Yau, Laura van ‘t Veer, W. Fraser Symmans, Melissa Paoloni, Jane Perlmutter, Nola M. Hylton, Michael Hogarth, Angela DeMichele, Meredith Buxton, A. Jo Chien, Anne M. Wallace, Judy C. Boughey, Tufia C. Haddad, Jane Yuet Ching Hui, Kathleen Kemmer, Henry G. Kaplan, Claudine Isaacs, Rita Nanda, Debasish Tripathy, Kathy S. Albain, Kirsten K. Edmiston, Anthony Elias, Donald W. Northfelt, Lajos Pusztai, Stacy L. Moulder, Julie E. Lang, Rebecca K. Viscusi, David Euhus, Barbara Haley, Qamar J. Khan, William C. Wood, Michelle Melisko, Richard B. Schwab, Teresa Helsten, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Laura J. Esserman, Donald A. Berry
New England Journal of Medicine. 2016465 CitationsOPEN ACCESS
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias, Heather Beckwith, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer, Kevin Kalinsky, Claudine Isaacs, Alexandra Thomas, Rebecca Shatsky, Theresa L. Helsten, Andres Forero‐Torres, Minetta C. Liu, Lamorna Brown Swigart, Emmanuel Petricoin, Julia Wulfkuhle, Smita Asare, Amy Wilson, Ruby Singhrao, Laura Sit, Gillian L. Hirst, Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman
Cancer Cell. 2021339 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account